Founded in 2020 by father-and-daughter duo Prof. Gordan Lauc and Nikolina Lauc, England-based GlycanAge analyzes glycans—complex sugars that coat cells and many proteins—to read inflammation-linked signals that drive ageing. Its flagship offering is an IgG glycosylation-based “inflammaging” clock that provides a detailed measure of biological age and tracks how lifestyle, environmental factors and chronic inflammation affect health over time. The company is now building indication-specific clinical tools for stress and resilience, cardiometabolic health, weight management and hormones, with plans to package these as products for practitioners. It is also validating diagnostic indications and preparing its first lab-developed tests for hospital and reference-lab use, supported by collaborations with Northwestern University Hospital and Mayo Clinic. A pilot is already live at St Catherine Specialty Hospital in Zagreb, and GlycanAge intends to roll out to more than 10 hospitals across Europe and the Middle East within a year. In Saudi Arabia, a partnership with the King Abdulaziz City for Science and Technology will host the firm’s first local laboratory to serve regional hospital networks. The company has raised at least €11.3 million to date, including a €3.9 million seed round in 2024 and the latest €7.4 million financing.

Total raised

$13M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2025